In Tuesday’s Wall Street session, TG Therapeutics Inc (NASDAQ:TGTX) shares traded at $34.86, down -7.48% from the previous session.
TGTX stock price is now -9.23% away from the 50-day moving average and 16.83% away from the 200-day moving average. The market capitalization of the company currently stands at $5.53B.
With the price target of $50, TD Cowen recently initiated with Buy rating for TG Therapeutics Inc (NASDAQ: TGTX). On August 02, 2023, Goldman Upgraded its previous ‘Sell’ rating to ‘Neutral’ on the stock reducing its target price from $16 to quote $12, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Power Sean A, CFO sold 11,337 shares of the company’s stock on Jan 03 ’25. The stock was sold for $343,443 at an average price of $30.29. Upon completion of the transaction, the CFO now directly owns 670,632 shares in the company, valued at $23.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 06 ’25, CFO Power Sean A sold 10,021 shares of the business’s stock. A total of $285,939 was realized by selling the stock at an average price of $28.53. This leaves the insider owning 660,611 shares of the company worth $23.03 million. A total of 9.96% of the company’s stock is owned by insiders.
During the past 12 months, TG Therapeutics Inc has had a low of $15.16 and a high of $46.48. As of last week, the company has a debt-to-equity ratio of 1.07, a current ratio of 6.25, and a quick ratio of 5.03.
The net profit margin was 10.13% and return on equity was 19.70% for TGTX. The company reported revenue of $108.19 million for the quarter, compared to $43.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 146.04 percent.
